American BriVision (Holding) Corporation, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, a combination therapy for triple negative breast cancer; ABV-1504 for major depressive disorders; ABV-1505 for attention deficit hyperactivity disorder; ABV-1703 for the treatment of pancreatic cancer; ABV-1702 to treat myelodysplastic syndromes; ABV-1601 for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company was incorporated in 2015 and is based in Fremont, California. American BriVision (Holding) Corporation is a subsidiary of YuanGene Corporation.
IPO Year:
Exchange: NASDAQ
Website: abvcpharma.com
• Executed Global Licensing Agreements that could provide up to $292 million in income • Received Cash Milestone Incomes of $116,000 • Achieved Significant Improvements in Earnings • Obtained Multiple Patents and FDA Approvals FREMONT, CA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, is pleased to announce its financial results and key operational highlights for the second quarter ended June 30, 2024. Key Financial and Operational Highlights: 1. Significant Global Licensing Agreements: - Vitargus® Licensing: Along with
USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, May 15, 2024 /PRNewswire/ -- USA News Group – Hope is rising in the fight against one of the deadliest cancers in the world, as a new study recently claimed that a blood test can accurately detect early-stage pancreatic cancer with 97% accuracy. According to Johns Hopkins Medicine, up to 10% of patients who receive an early diagnosis become disease-free after treatment, meaning the earlier it's detected, the better the patient's chances to survive. The American Cancer Society estimates that about 66,440 people (34,530 men and 31,910 women) will be diagnosed with pancreatic cancer in the USA this year, projec
FREMONT, CA, April 18, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company's subsidiary AiBtl BioPharma Inc. acquired TT Life Company, an established player in the precision medicine industry. The acquisition includes Malaysian Import Trading Company, Direct Sales Company, and Taiwanese Direct Sales Company, which are estimated to be approximately equivalent to $8.33M. AiBtl purchased 100% shares of TT Life by swapping its 1.66M shares at $5 per share. This strategic mov
FREMONT, CA, April 17, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company, together with its affiliate Rgene Corporation entered into a comprehensive licensing agreement with OncoX, a private company registered in the British Virgin Islands that specializes in dietary supplements for Oncology. We are hopeful that this agreement will facilitate the advancement of treatments for Non-Small Cell Lung Cancer (NSCLC) since it covers the license for the clinical trial, regist
FREMONT, CA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company together with its affiliates BioLite, Inc., and Rgene Corporation entered into a term sheet with OncoX BioPharma, Inc. (OncoX) for the Company's Oncology/Hematology pipeline(the "Licensed Products"). Subject to negotiation and execution of the definitive agreement, this license would cover the Licensed Products' clinical trial, registration, manufacturing, supply, and distribution rights. ABVC is
FREMONT, CA, March 26, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that each of the Company and its subsidiary BioFirst Corporation entered into a global licensing agreement with ForSeeCon Eye Corporation (FEYE) for the Company's Ophthalmology pipeline, which includes the medical device Vitargus® (valued at $187M, by third-party valuer) (the "Licensed Products"). This license will cover the Licensed Products' clinical trial, registration, manufacturing, supply, and distribution r
FREMONT, CA, March 21, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that one of its subsidiaries, AiBtl BioPharma Inc. (AIBL), entered into an Agreement to exchange a 100% ownership stake in certain real estate for 1,533,333 shares of AIBL stock at $5 per share. The property is valued at approximately $7.6 million based on a third-party valuation. "We are extremely pleased with AIBL's entry into this agreement and valuations. ABVC and its subsidiary BioLite, Inc. each own 23M AIBL shares, and we
FREMONT, CA, March 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, proudly announced today that its CEO, Dr. Uttam Patil, was selected as one of the Top 10 CEOs in Taiwan 2024 by CEO Insights Asia Magazine. This recognition is a testament to Dr. Patil's outstanding leadership, innovative vision, and significant contributions to the Company. Dr. Patil is confident in the Company's prospects, so he owns stock options without claiming a salary. Within his first year as the Company's CEO, the Company saw a rise in the stock
FREMONT, CA, March 14, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes, announced its 2023 annual financial and operating results. These results, including the financial statements included herein, can be found in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 13, 2024. 2023 Annual Financial Results All comparisons are made on a year-over-year basis. Licensing Deal: On November 12, 2023, the Company and one of its subsidiaries, BioLite, Inc. ("B
FREMONT, CA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, today provided an update on its development of combination therapy for the treatment of cancer and immunity booster dietary supplements. The Company is currently marketing dietary supplements, as well as continuing to pursue clinical trials of pharmaceutical compounds; both of which are derived from the same source: Maitake Mushroom. The Company expects to initiate clinical trials at several prestigious medical institutes in the U
8-K - ABVC BIOPHARMA, INC. (0001173313) (Filer)
8-K - ABVC BIOPHARMA, INC. (0001173313) (Filer)
424B4 - ABVC BIOPHARMA, INC. (0001173313) (Filer)
424B4 - ABVC BIOPHARMA, INC. (0001173313) (Filer)
424B4 - ABVC BIOPHARMA, INC. (0001173313) (Filer)
8-K - ABVC BIOPHARMA, INC. (0001173313) (Filer)
10-Q - ABVC BIOPHARMA, INC. (0001173313) (Filer)
424B5 - ABVC BIOPHARMA, INC. (0001173313) (Filer)
424B5 - ABVC BIOPHARMA, INC. (0001173313) (Filer)
EFFECT - ABVC BIOPHARMA, INC. (0001173313) (Filer)
SC 13G/A - ABVC BIOPHARMA, INC. (0001173313) (Subject)
SC 13G - ABVC BIOPHARMA, INC. (0001173313) (Subject)
SC 13D - ABVC BIOPHARMA, INC. (0001173313) (Subject)
FREMONT, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it signed a definitive agreement to acquire real estate in Taoyuan City, Taiwan. The acquisition of real estate assets, estimated at approximately $2.96 million via an equity transfer of $3.50 per share, is to develop plant factories for ABVC's botanical pipeline strategically; ABVC hopes the property will ultimately be used as an integrated platform for the global development of the Asian healthcare business and the medical, pha
3 - ABVC BIOPHARMA, INC. (0001173313) (Issuer)
3 - ABVC BIOPHARMA, INC. (0001173313) (Issuer)
3 - ABVC BIOPHARMA, INC. (0001173313) (Issuer)
3 - ABVC BIOPHARMA, INC. (0001173313) (Issuer)
3 - ABVC BIOPHARMA, INC. (0001173313) (Issuer)
3 - ABVC BIOPHARMA, INC. (0001173313) (Issuer)
3 - ABVC BIOPHARMA, INC. (0001173313) (Issuer)
3 - ABVC BIOPHARMA, INC. (0001173313) (Issuer)
3 - ABVC BIOPHARMA, INC. (0001173313) (Issuer)
3 - ABVC BIOPHARMA, INC. (0001173313) (Issuer)
FREMONT, CA, Nov. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that it entered into a global licensing definitive agreement with AiBtl BioPharma Inc. (AiBtl) for the Company's CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (the "Licensed Products"). The agreement has the potential of licensing income worth $467M and royalties up to $200M. The Licensed Products for MDD and ADHD, owned by ABVC and its su
FREMONT, CA, June 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the appointment of Dr. Uttam Yashwant Patil (Dr. Uttam) as the new Chief Executive Officer (CEO). Dr. Uttam is very familiar with ABVC and their subsidiaries, because of his role as Chief Operating Officer & Chief Scientific Officer of BioKey, Inc., a GMP-certified facility owned by ABVC that provides its clients with integrated pharmaceutical services, including early-phase product development, formulation development, analytical development & d
- SEC Filing
https://www.sec.gov/ix?doc=/Archives/edgar/data/1173313/000121390024041053/ea0205569-8k_abvcbio.htm
Shares of Tesla, Inc. (NASDAQ:TSLA) rose sharply in today's pre-market trading following first-quarter results. Tesla posted weaker-than-expected earnings and sales results for its first quarter on Tuesday. The electric vehicle giant also announced plans to speed up the launch of new models. Tesla shares jumped 10.6% to $160.01 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Chicken Soup for the Soul Entertainment, Inc. (NASDAQ:CSSE) shares gained 49.4% to $0.2276 in pre-market trading after gaining over 8% on Tuesday. Zapata Computing Holdings Inc. (NASDAQ:ZPTA) gained 30.8% to $2.04 in pre-market trading after declining 10% on Tues
Gainers 180 Life Sciences (NASDAQ:ATNF) shares moved upwards by 7.4% to $2.04 during Tuesday's after-market session. The market value of their outstanding shares is at $1.7 million. ABVC BioPharma (NASDAQ:ABVC) shares rose 5.22% to $1.42. The company's market cap stands at $15.0 million. Medpace Hldgs (NASDAQ:MEDP) stock increased by 5.15% to $427.5. The company's market cap stands at $13.2 billion. The company's, Q1 earnings came out yesterday. Adverum Biotechnologies (NASDAQ:ADVM) stock increased by 5.0% to $11.55. The market value of their outstanding shares is at $239.7 million. Black Diamond Therapeutic (NASDAQ:BDTX) stock moved upwards by 4.99% to $5.26. The market value of their
ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company's subsidiary AiBtl BioPharma Inc. acquired TT Life Company, an established player in the precision medicine industry. The acquisition includes Malaysian Import Trading Company, Direct Sales Company, and Taiwanese Direct Sales Company, which are estimated to be approximately equivalent to $8.33M. AiBtl purchased 100% shares of TT Life by swapping its 1.66M shares at $5 per share. This strategic move positions AiBtl to expand its portfolio further and accelerate inno
ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company, together with its affiliate Rgene Corporation entered into a comprehensive licensing agreement with OncoX, a private company registered in the British Virgin Islands that specializes in dietary supplements for Oncology. We are hopeful that this agreement will facilitate the advancement of treatments for Non-Small Cell Lung Cancer (NSCLC) since it covers the license for the clinical trial, registration, manufacturing, supply, and distribution rights of ABVC's singl
Gainers Rallybio (NASDAQ:RLYB) shares rose 31.9% to $2.15 during Wednesday's after-market session. The company's market cap stands at $81.2 million. Vera Therapeutics (NASDAQ:VERA) shares increased by 10.52% to $46.0. The market value of their outstanding shares is at $2.5 billion. Biophytis (NASDAQ:BPTS) stock rose 9.49% to $0.37. The company's market cap stands at $4.2 million. IMAC Hldgs (NASDAQ:BACK) shares rose 7.35% to $3.02. The company's market cap stands at $3.4 million. Relay Therapeutics (NASDAQ:RLAY) stock moved upwards by 7.1% to $7.39. The company's market cap stands at $969.4 million. Adial Pharmaceuticals (NASDAQ:ADIL) shares rose 6.43% to $2.48. The company's market ca
ADIL: 108% | Adial Pharmaceuticals shares are trading higher after the company announced the publication of a peer-reviewed article highlighting the clinical results, strong safety profile, and high compliance among patients administered AD04. NA: 70% | Nano Labs Files Annual Report on Form 20-F for Fiscal Year 2023 ABVC: 33% | ABVC BioPharma Executes A Global Licensing Term Sheet For Oncology/Hematology Products, Expecting Licensing Income Of $55M And Royalties Of Up To $50M
ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company together with its affiliates BioLite, Inc., and Rgene Corporation entered into a term sheet with OncoX BioPharma, Inc. (OncoX) for the Company's Oncology/Hematology pipeline(the "Licensed Products"). Subject to negotiation and execution of the definitive agreement, this license would cover the Licensed Products' clinical trial, registration, manufacturing, supply, and distribution rights. ABVC is set to receive $50,000,000 as licensing fees in the form of Cash/Sha
Gainers OpGen (NASDAQ:OPGN) shares moved upwards by 24.0% to $0.74 during Monday's after-market session. The market value of their outstanding shares is at $7.4 million. Galecto (NASDAQ:GLTO) shares increased by 9.93% to $0.82. The market value of their outstanding shares is at $22.2 million. Kyverna Therapeutics (NASDAQ:KYTX) shares increased by 9.19% to $24.59. The company's market cap stands at $1.0 billion. Matinas BioPharma Hldgs (AMEX:MTNB) stock increased by 8.16% to $0.4. The company's market cap stands at $86.9 million. The company's, Q4 earnings came out 3 days ago. Ontrak (NASDAQ:OTRK) shares rose 7.86% to $0.48. The company's market cap stands at $13.2 million. Apollomics (